Imatinib resistance and blast transformation of chronic myeloid leukemia associated with a novel tri-nucleotide insertion mutation of BCR-ABL kinase domain at position K294

A letter to the editor is presented which discusses the introduction of imatinib mesylate (IM) in the medical case of an 18-year old man with in-frame mutations and blast transformation of chronic myeloid leukemia (CML).